SSSara Saberi

Sara Saberi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara Saberi has a total of 276 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of Clinical Characteristics Between Patients With HCM With Nontruncating Versus Truncating Variants in MYBPC3

    by Trisha T. Phan, Carolyn Ho, Neal Lakdawala, Anjali Owens, Adam Helms, Sara Saberi, Mark W. Russell, Rachel Lampert, John C. Stendahl, Vicki Parikh, et al.

  • Clinical Characteristics and Outcomes of Hypertrophic Cardiomyopathy Associated With Thin Filament Variants: Insights From the SHaRe Registry

    by Alessia Argirò, Joshua K. Meisner, Eric D. Adler, Edoardo Bertero, Niccolò Maurizi, Brian L. Claggett, Neal K. Lakdawala, Anjali T. Owens, Thomas D. Ryan, Erin M. Miller, et al.

    BACKGROUND: Conflicting evidence exists about whether sarcomeric hypertrophic cardiomyopathy (HCM) caused by genes encoding thin filament proteins ( TNNT2, TNNI3, ACTC, TPM1 , TNNC1 ; thin filament HCM) has a distinct clinical presentation and natural history from disease caused by the more commonly involved thick filament genes ( MYH7 , MYBPC3 , MYL2 , MYL3 ; thick filament HCM). METHODS: Retrospective analysis of the Sarcomeric Human Cardiomyopathy Registry. RESULTS: Four hundred eighty-eight patients with thin filament HCM were compared with 3494 patients with thick filament HCM. After controlling for age at diagnosis, sex, and proband status, thin filament HCM was associated with a higher risk of composite ventricular arrhythmias (hazard ratio, 1.48 [95% CI, 1.09–2.01]), cardiac arrest (hazard ratio, 2.02 [95% CI, 1.33–3.06]), and heart transplant or left ventricular assist device implantation (hazard ratio, 2.18 [95% CI, 1.3–3.65]). Younger age at diagnosis was associated with an increased risk for the ventricular arrhythmia composite outcome in thin and thick filament HCM (hazard ratio, 0.93 [95% CI, 0.91–0.94]; hazard ratio, 0.93 [95% CI, 0.93–0.94]; age reported as 5-year increment). Within specific thin filament genes, an increased risk of arrhythmic events or heart transplant/left ventricular assist device implantation was evident for variants in TNNT2 amino acids 92 to 94 (odds ratio versus other TNNT2 variants; odds ratio, 3.02 [95% CI, 1.17–7.49]) and TNNI3 amino acids 191 to 210 (odds ratio versus other TNNI3 variants; odds ratio, 3.5 [95% CI, 1.58–8.02]). CONCLUSIONS: Thin filament HCM seems to carry a higher risk for ventricular arrhythmias and advanced heart failure compared with thick filament HCM. Integrating gene-level and intragene-level information may improve risk stratification in patients with HCM.

  • Open Access

    Aficamten Reduces Eligibility for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy: Long-Term Outcomes from FOREST-HCM

    by Ahmad Masri, Benjamin Meder, Lubna Choudhury, Pablo Garcia-Pavia, Theodore P. Abraham, Roberto Barriales-Villa, Ozlem Bilen, Perry Elliott, Albert A. Hagege, Sherif F. Nagueh, et al.

    Background: Septal reduction therapy (SRT) is recommended in drug-refractory, symptomatic obstructive hypertrophic cardiomyopathy (oHCM). We evaluated whether aficamten, a novel cardiac myosin inhibitor, can reliably transition guideline-eligible SRT candidates to ineligibility, and the associated safety profile of aficamten in this group. Methods: We analyzed participants with oHCM enrolled in FOREST-HCM ( NCT04848506 ), the long-term open-label extension study of aficamten, from 28 May 2021 to 9 May 2025. Results: Three hundred and fifteen patients were included, of whom 104 met 2024 ACC/AHA guideline criteria for SRT eligibility at baseline. The SRT-eligible cohort was predominantly female (57%), with mean resting and Valsalva left ventricular outflow tract (LVOT) gradients of 63 ± 39 and 109 ± 42 mmHg, and all were in New York Heart Association (NYHA) class III. All baseline SRT-eligible patients became SRT-ineligible with aficamten therapy during study follow-up over a median of 42 days (IQR: 17, 49), except for one participant who withdrew from the study to pursue SRT (total of 3 participants withdrew). After dose titration, 3/104 (2.9%) remained guideline-eligible; by week 72 no patients met eligibility criteria. At maintenance, resting and Valsalva LVOT gradients improved by a least-squares mean of −41 mmHg ([95% CI −44 to −37]; P< 0.0001) and −56 mmHg ([95% CI −62 to −51]; P< 0.0001), respectively. Relative to baseline, NT-proBNP improved by 77% (95% CI 74 – 80%), high-sensitivity cardiac troponin I decreased by 38% (95% CI 30 – 46%), KCCQ-CSS improved by a mean of 20.2 (SD 19.3) points, and 95.2% of SRT-eligible patients had improved by ≥1 NYHA class. Overall, the safety profile was favorable, with 2 occurrences of left ventricular ejection fraction (LVEF) < 50% over 193.7 patient-years of follow-up (1 event per 100 patient-years), managed by down-titration. There were no baseline SRT-eligible patients who died or developed LVEF ClinicalTrials.gov , NCT04848506 ( https://clinicaltrials.gov/study/NCT04848506 ); Date of registration: April 19, 2021 Clinical Perspective: What is new?: - Aficamten is a cardiac myosin inhibitor that improved symptoms and left ventricular outflow tract gradients in almost all patients who were eligible for septal reduction therapy (SRT) in the FOREST-HCM trial. - Aficamten was safe with rare reduction in systolic function and no heart failure events. What are the clinical implications?: - Aficamten can be used as an alternative to patients who are eligible for SRT.

  • Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCM

    by Sara Saberi, Srihari S. Naidu, Iacopo Olivotto, Albert A. Hagège, Yue Zhong, Jenny Lam, Kathleen W. Wyrwich, Jennifer T. Fine, Chantal Dolan, Veleka Allen, et al.


  • The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis

    by Robert Przybylski, Gabrielle Norrish, Brian Claggett, Euan A. Ashley, Vinay Bhole, Sharlene M. Day, Grazia Delle Donne, Adrian Fernandez, Francesca Girolami, Belinda Gray, et al.

    BACKGROUND: Massive left ventricular hypertrophy (LVH) is a risk factor for sudden cardiac death in children with hypertrophic cardiomyopathy (HCM), but little is understood about its natural history. METHODS: Patients with pediatric-onset HCM identified from 2 registries (SHaRe [Sarcomeric Human Cardiomyopathy Registry] and IPHCC [International Paediatric Hypertrophic Cardiomyopathy Consortium]) with or without massive LVH were compared. Massive LVH was defined as absolute maximal left ventricular wall thickness (MLVWT) ≥30 mm or MLVWT z score ≥+20 at P P =0.034), as was HCM-related mortality (unadjusted hazard ratio, 3.3 [95% CI,1.2–9.7]; P =0.026), major adverse cardiac events (hazard ratio, 2.6 [1.7–3.9]; P P P =0.013). These associations remained significant when adjusted for sex and age at HCM diagnosis. In 115 patients with massive LVH with serial MLVWT data (62%), MLVWT increased significantly from first to last measurements (median, 26 mm [interquartile range, 18–32 mm] versus 31 mm [26–35 mm]; P 5 mm less than the largest recorded MLVWT in 25 patients (22%). CONCLUSIONS: In pediatric HCM, massive LVH disproportionately affects those diagnosed in early childhood with sarcomeric disease, with increased risk for adverse events. Significant MLVWT regression is seen in nearly a quarter of patients.

  • Top Cited Papers

    Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy

    by Christoffer R. Vissing, Anna Axelsson Raja, Adam S. Helms, Sara Saberi, Anjali T. Owens, Joseph W. Rossano, Dominic J. Abrams, Jodie Ingles, Belinda Gray, Rachel Lampert, et al.

    BACKGROUND: Sarcomere gene variants are a key cause of hypertrophic cardiomyopathy (HCM), and have been associated with worse prognosis. However, it is unclear how comorbidities influence clinical trajectories, the timing of events, and causes of death in sarcomeric and nonsarcomeric HCM. METHODS: We conducted a multicenter longitudinal cohort study of genotyped patients with HCM in the Sarcomeric Human Cardiomyopathy registry (SHaRe). Patients were classified as sarcomeric HCM (pathogenic/likely pathogenic sarcomere variant) or nonsarcomeric HCM (genetically elusive). The influence of genetic classification and comorbidities on the sequence of cardiovascular events were assessed in time-varying Cox proportional hazards models. RESULTS: Among 6120 patients (40% women; 87% probands; 50% sarcomeric HCM), followed for a median of 5.3 years, sarcomeric HCM (n=3082) was associated with a younger age at diagnosis (median 38.1 versus 54.3 years; P P =0.20); however, patients with sarcomeric HCM died younger (mean 7.8 years; P P <0.01). CONCLUSIONS: Genotype can refine risk stratification and inform clinical management in HCM. Sarcomeric HCM is associated with worse prognosis and may benefit from more vigilant surveillance for arrhythmias and systolic dysfunction, with a lower threshold for advanced therapies. Comorbidities, including hypertension and obesity, may be modifiable risk factors for patients with nonsarcomeric HCM.


  • Open Access

    Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM

    by Xiaowen Wang, Maria A. Pabon, Tracy T. Makuvire, Reziwanguli Maimaiti, Theodore P. Abraham, Roberto Barriales-Villa, Brian L. Claggett, Caroline J. Coats, Martin S. Maron, Ahmad Masri, et al.

    BACKGROUND: Women with obstructive hypertrophic cardiomyopathy often present with a greater burden of disease and worse prognosis. Whether there are sex-related differences in response to aficamten is unknown. METHODS: We performed a prespecified subgroup analysis of sex differences in the double-blind, randomized-controlled SEQUOIA-HCM trial (Safety, Efficacy and Quantitative Understanding of Obstruction Impact of Aficamten in HCM) of aficamten versus placebo in patients with obstructive hypertrophic cardiomyopathy. Baseline characteristics were compared using the t test for continuous variables and the χ 2 test for categorical variables. Prespecified primary (change in peak oxygen uptake) and secondary end points from baseline to end of treatment (week 24) were analyzed using linear regression models, adjusted for baseline values, β-blocker use, and exercise mode. RESULTS: Of the 282 participants, women (n=115) were older (64 years in women versus 56 years in men) and had lower Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, and lower peak oxygen uptake at baseline. Women had smaller left ventricular chamber sizes, higher E/e’ ratios, and higher left ventricular outflow tract gradients. At 24 weeks, there was a significant treatment-related increase in peak oxygen uptake in women (+1.5 [+0.7 to +2.4]) and men (+2.0 [+0.9 to +3.0]). Both women and men had significant treatment-related decreases in left ventricular outflow tract gradients at rest and with Valsalva, with no sex-by-treatment interaction at week 24 ( P interaction ≥0.13). There was a significant improvement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score in women (11 [6–15]) and men (6 [2–9]; P interaction =0.08). Women had a greater reduction in lateral E/e’ ratio ( P interaction =0.01). The geometric mean proportional reduction in NT-proBNP was similar in women and men ( P interaction =0.10). CONCLUSIONS: Women enrolled in SEQUOIA-HCM were older with worse baseline health status, higher NT-proBNP, and higher left ventricular outflow tract gradients compared with men. Despite these differences, both men and women derived significant benefits in the primary and secondary end points following treatment with aficamten.


  • Open Access

    Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy

    by Sara Saberi, Christopher M. Kramer, Artur OręZiak, Ahmad Masri, Roberto Barriales-Villa, Theodore P. Abraham, Neal K. Lakdawala, Andrew Wang, Lubna Choudhury, Florian Rader, et al.


  • Open Access

    Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis

    by Isabela Landsteiner, Ahmad Masri, Sara Saberi, Martin S. Maron, Shaina Lyn McGinnis, Catharine Griskowitz, Chloe Elizabeth Newlands, Roberto Barriales‐Villa, Anjali T. Owens, Gregory D. Lewis

    Background: Hypertrophic cardiomyopathy (HCM) is associated with substantial risk of adverse cardiac events. Consequently, detailed physiologic assessment and accurate risk stratification in HCM are of high clinical importance. This systematic review and meta‐analysis synthesizes current evidence on the utility of cardiopulmonary exercise testing (CPET) for characterization and prognostication of HCM. Methods: PubMed, Embase, Scopus, and Web of Science were systematically searched for eligible studies from database inception to November 2023. The primary outcome of mortality was assessed using meta‐analyzed hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional hazard models. Results: Sixty full‐length articles focusing on CPETs performed in patients with HCM were included, comprising 12 914 patients. Despite male predominance (66%) and a mean age of 48 years, peak oxygen uptake (pVO 2 ) was only 22.4 mL/kg per min (95% CI, 22.3–22.5), consistent with significant functional limitation. Compared with commonly used metrics such as New York Heart Assocation functional class, CPET markedly enhances sensitivity to detect impaired cardiac performance. This meta‐analysis highlights easily derived CPET variables that predict HCM prognosis. For the primary outcome, the hazard ratio per 1‐mL/kg per min difference in pVO₂ was 0.86 (95% CI, 0.82–0.90; P P 20 mm Hg, was associated with an HR of 2.29 (95% CI, 1.13–4.64; P =0.02) for mortality. Conclusions: CPET is a valuable objective method for multidimensional physiologic assessment and prognostication in HCM. With further standardization, CPET is well suited for more widespread clinical utilization in patients with HCM.